Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Mixed Quarterly Earnings Amidst Strong Revenue Growth

Font: Financial Modeling Prep  • Aug 03, 2026

• Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company, is expanding its focus beyond cystic fibrosis into areas like sickle cell disease and rare endocrine diseases.
• The company reported a slight miss on quarterly earnings per share (EPS) at $4.73 but significantly surpassed revenue estimates with $3.33 billion, driven by strong demand for its cystic fibrosis treatments.
• Vertex Pharmaceuticals demonstrates robust financial health with a low debt-to-equity ratio of 0.07 and a strong current ratio of 3.19, alongside a P/E ratio of 27.18 and a P/S ratio of 9.46.

Vertex Pharmaceuticals (NASDAQ:VRTX) is a global biotechnology company that develops medicines for serious diseases. Vertex Pharmaceuticals is a leader in treatments for cystic fibrosis and is expanding into other areas. These include sickle cell disease, acute pain, and rare endocrine diseases through a pending acquisition.

On August 3rd, 2026, Vertex Pharmaceuticals reported quarterly earnings of $4.73 per share. This figure narrowly missed the analyst consensus estimate of $4.74. This slight miss on earnings contributed to what was seen as a mixed quarterly report, as highlighted by Investors.com.

Vertex Pharmaceuticals announced quarterly revenue of $3.33 billion, surpassing the analyst consensus estimate of $3.23 billion. Following this strong revenue performance, Vertex Pharmaceuticals raised its annual revenue forecast. As highlighted by Reuters, this is due to robust demand for its cystic fibrosis treatments.

From a valuation standpoint, Vertex Pharmaceuticals has a price-to-earnings (P/E) ratio of 27.18. The P/E ratio shows how much investors are willing to pay for each dollar of the company's earnings. Its price-to-sales (P/S) ratio, which compares the stock price to revenues, is 9.46.

The company's financial health appears stable. It has a low debt-to-equity ratio of 0.07, which means it uses very little debt to finance its assets. Furthermore, its current ratio of 3.19 shows it has more than enough resources to cover its short-term obligations.